[go: up one dir, main page]

AR027234A1 - Derivados de la toxina clostridial y metodos para el tratamiento del dolor - Google Patents

Derivados de la toxina clostridial y metodos para el tratamiento del dolor

Info

Publication number
AR027234A1
AR027234A1 ARP010100202A ARP010100202A AR027234A1 AR 027234 A1 AR027234 A1 AR 027234A1 AR P010100202 A ARP010100202 A AR P010100202A AR P010100202 A ARP010100202 A AR P010100202A AR 027234 A1 AR027234 A1 AR 027234A1
Authority
AR
Argentina
Prior art keywords
methods
pain
derivatives
treatment
clostridial toxin
Prior art date
Application number
ARP010100202A
Other languages
English (en)
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of AR027234A1 publication Critical patent/AR027234A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/22—Tachykinins, e.g. Eledoisins, Substance P; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Los agentes para tratar el dolor, los métodos para producir los agentes y los métodos para tratar el dolor por la administracion a un paciente de unacantidad terapéuticamente efectiva del agente. El agente puede incluir una neurotoxina clostridial, o un componente o un fragmento o derivado de la misma,unido a un grupo activo, donde el grupo activo es seleccionado de un grupo que consiste de compuestos de transmision que pueden ser liberados de las neuronasen la transmision de las senales del dol or por las neuronas y los compuestos substancialmente similares a los compuestos de transmision.
ARP010100202A 2000-01-19 2001-01-17 Derivados de la toxina clostridial y metodos para el tratamiento del dolor AR027234A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/489,667 US7138127B1 (en) 2000-01-19 2000-01-19 Clostridial toxin derivatives and methods for treating pain

Publications (1)

Publication Number Publication Date
AR027234A1 true AR027234A1 (es) 2003-03-19

Family

ID=23944774

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010100202A AR027234A1 (es) 2000-01-19 2001-01-17 Derivados de la toxina clostridial y metodos para el tratamiento del dolor

Country Status (4)

Country Link
US (13) US7138127B1 (es)
AR (1) AR027234A1 (es)
AU (1) AU2001227930A1 (es)
WO (1) WO2001053336A1 (es)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7227010B2 (en) * 1993-09-21 2007-06-05 United States Of America As Represented By The Secretary Of The Army Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
US6967088B1 (en) * 1995-03-16 2005-11-22 Allergan, Inc. Soluble recombinant botulinum toxin proteins
US7192596B2 (en) * 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
GB9617671D0 (en) * 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US20060216313A1 (en) * 1999-08-10 2006-09-28 Allergan, Inc. Methods for treating a stricture with a botulinum toxin
KR100876060B1 (ko) * 1999-08-25 2008-12-26 알러간, 인코포레이티드 활성화가능한 재조합 신경독
WO2001047512A2 (en) * 1999-12-08 2001-07-05 Fluoro Probe, Inc. Method for relieving pain associated with an internal disease site
US7138127B1 (en) * 2000-01-19 2006-11-21 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
DE10019157A1 (de) * 2000-04-18 2001-11-15 Stefan Duebel Verfahren zum Einbringen von Liganden in lebende Zellen
US6423319B1 (en) * 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
US7273722B2 (en) * 2000-11-29 2007-09-25 Allergan, Inc. Neurotoxins with enhanced target specificity
US7022329B2 (en) * 2002-02-25 2006-04-04 Allergan, Inc. Method for treating neurogenic inflammation pain with botulinum toxin and substance P components
WO2004010934A2 (en) * 2002-07-29 2004-02-05 Rajiv Doshi Methods for the use of neurotoxin in the treatment of urologic disorders
US20040086532A1 (en) * 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
CN1972704A (zh) * 2004-04-26 2007-05-30 免疫再生生物科学有限公司 P物质的抗衰老作用
US7811584B2 (en) * 2004-06-30 2010-10-12 Allergan, Inc. Multivalent clostridial toxins
DE102004043009A1 (de) 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
US7659092B2 (en) * 2004-12-01 2010-02-09 Syntaxin, Ltd. Fusion proteins
GB0426394D0 (en) * 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
US8512984B2 (en) 2004-12-01 2013-08-20 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8778634B2 (en) 2004-12-01 2014-07-15 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8399400B2 (en) 2004-12-01 2013-03-19 Syntaxin, Ltd. Fusion proteins
US8603779B2 (en) 2004-12-01 2013-12-10 Syntaxin, Ltd. Non-cytotoxic protein conjugates
JP2008535486A (ja) * 2005-03-15 2008-09-04 アラーガン、インコーポレイテッド クロストリジウム毒素標的細胞に対する改変された標的能力を有する修飾クロストリジウム毒素
US8021859B2 (en) * 2005-03-15 2011-09-20 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
DE102005019302A1 (de) 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
GB0610867D0 (en) 2006-06-01 2006-07-12 Syntaxin Ltd Treatment of pain
EP2505592A1 (en) 2006-07-11 2012-10-03 Allergan, Inc. Modified clostridial toxins with enhanced translocation capability and enhanced targeting activity
JP2009543557A (ja) * 2006-07-11 2009-12-10 アラーガン、インコーポレイテッド 増強した転位置能力およびクロストリジウム毒素標的細胞に対する変化したターゲティング活性を有する改変クロストリジウム毒素
SG185338A1 (en) * 2007-10-23 2012-11-29 Allergan Inc Methods of treating urogenital-neurological disorders using modified clostridial toxins
BRPI0819212A2 (pt) * 2007-10-23 2015-06-16 Allergan Inc Métodos de tratamento de inflamação neurogênica crônica usando toxinas modificadas de clostrídio
EP3473643A1 (en) 2008-06-12 2019-04-24 Ipsen Bioinnovation Limited Fusion proteins for use in the treatemnt of cancer
US8796216B2 (en) 2008-06-12 2014-08-05 Syntaxin Limited Suppression of neuroendocrine diseases
US9478108B2 (en) * 2008-11-10 2016-10-25 Archangel Device Llc Multi-directional, multi-functional, wearable safety lighting apparatus
PT3281953T (pt) * 2009-03-13 2020-01-15 Allergan Inc Ensaios de base imunológica da actividade de endopeptidase redireccionada
US20100303798A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Urogenital-Neurological Disorders Using Neurotrophin Retargeted Endopepidases
US20100303788A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Galanin Retargeted Endopepidases
US20100303789A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Neurotrophin Retargeted Endopepidases
US20100303783A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Urogenital-Neurological Disorders Using Tachykinin Retargeted Endopepidases
US20100303791A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Glucagon Like Hormone Retargeted Endopepidases
US20100303794A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Urogenital-Neurological Disorders Using Glucagon Like Hormone Retargeted Endopepidases
WO2011041779A1 (en) 2009-10-02 2011-04-07 Allergan, Inc. In vitro method of determining changes in a protein environment
SI2528940T1 (sl) 2010-01-25 2014-07-31 Allergan, Inc. Metode znotrajcelične pretvorbe enoverižnih beljakovin v njihovo dvoverižno obliko
CA2799969C (en) 2010-05-20 2019-06-25 Allergan, Inc. Degradable clostridial toxins
US20130330369A1 (en) 2010-10-08 2013-12-12 Allergan, Inc. Reduction Of Antibody Response Against Botulinum Neurotoxin And Variants Thereof
EP2627350A1 (en) 2010-10-14 2013-08-21 Allergan, Inc. Targeted delivery of targeted exocytosis modulators to the sphenopalatine ganglion for treatment of headache disorders
ES2634669T3 (es) 2011-02-08 2017-09-28 Halozyme, Inc. Composición y formulación lipídica de una enzima de degradación de hialuronano y uso de la misma para el tratamiento de la hiperplasia benigna de próstata
US20120244188A1 (en) 2011-03-25 2012-09-27 Allergan, Inc. Treatment of Sensory Disturbance Disorders
US20120251573A1 (en) 2011-03-28 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Neuroendocrine Disorders
US20120251574A1 (en) 2011-03-28 2012-10-04 Allergan, Inc. Endopeptidase and Neurotoxin Combination Treatment of Multiple Medical Conditions
US20120251575A1 (en) 2011-03-28 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Involuntary Movement Disorders
WO2012135304A1 (en) 2011-03-29 2012-10-04 Allergan, Inc. Vagal nerve-based disorders
US20120251519A1 (en) 2011-03-29 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Smooth Muscle Disorders
US20120251515A1 (en) 2011-03-29 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Cosmesis Disorders
US20120251518A1 (en) 2011-03-29 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Sexual Dysfunction Disorders
WO2012174123A1 (en) 2011-06-13 2012-12-20 Allergan, Inc. Treatment of psychological trauma
US20130171122A1 (en) 2011-12-29 2013-07-04 Allergan, Inc. Endopeptidase and neurotoxin combination treatment of bladder disorders
US20140056870A1 (en) 2012-08-27 2014-02-27 Allergan, Inc. Fusion proteins
WO2014100019A1 (en) 2012-12-18 2014-06-26 Allergan, Inc. Prophylactic treatment of herpes recurrence
US9447405B2 (en) 2013-03-08 2016-09-20 Wisconsin Alumni Research Foundation Regulation of specific spinal neurons regulating pain transmission via chimeric toxins
US10501589B2 (en) 2013-09-12 2019-12-10 Northeastern University Nanostructured bacteria-resistant polymer materials
CA2969463A1 (en) * 2014-12-09 2016-06-16 New York University Clostridial neurotoxin fusion proteins, propeptide fusions, their expression, and use
US20170209553A1 (en) 2016-01-22 2017-07-27 Transderm, Inc. Delivery of botulinum with microneedle arrays
CN109414434A (zh) * 2016-05-13 2019-03-01 德尔诺瓦股份有限公司 化学去神经化所致的副作用的治疗
TW201814045A (zh) 2016-09-16 2018-04-16 英商艾普森生物製藥有限公司 製造雙鏈梭狀芽孢桿菌神經毒素之方法
US20210277071A1 (en) 2016-09-29 2021-09-09 Ipsen Biopharm Limited Hybrid neurotoxins
EP3312290A1 (en) 2016-10-18 2018-04-25 Ipsen Biopharm Limited Cellular vamp cleavage assay
CA3152024A1 (en) * 2019-08-30 2021-03-04 AEON Biopharma, Inc. Neurotoxin compositions for use in treating headache
AR133291A1 (es) * 2023-07-19 2025-09-17 Inst Pasteur De Montevideo Inmunización activa para el tratamiento de la dermatitis atópica

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US466244A (en) * 1891-12-29 kelly
US4189426A (en) 1976-04-12 1980-02-19 Hoffmann-La Roche, Inc. Recombinant hormonal compositions and method
US4481139A (en) * 1983-04-13 1984-11-06 Board Of Regents, The University Of Texas System Peptide antagonists of substance P
US4664911A (en) 1983-06-21 1987-05-12 Board Of Regents, University Of Texas System Immunotoxin conjugates employing toxin B chain moieties
JPS60248659A (ja) 1984-05-25 1985-12-09 Microbial Chem Res Found ３−〔ｎ−（メルカプトアシル）〕アミノ−４−アリ−ル酪酸誘導体及びそれを有効成分とする鎮痛剤
US5668255A (en) 1984-06-07 1997-09-16 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US5410019A (en) * 1987-09-24 1995-04-25 The Administrators Of The Tulane-Educational Fund Therapeutic peptides
ATE138102T1 (de) 1991-02-19 1996-06-15 Takeda Chemical Industries Ltd Verfahren zur herstellung von cysteinfreien peptiden
CA2112130C (en) 1991-06-27 1996-08-06 Cynthia A. Edwards Screening assay for the detection of dna-binding molecules
GB9305735D0 (en) 1993-03-19 1993-05-05 North John R Novel agent for controlling cell activity
US5891842A (en) 1993-04-09 1999-04-06 Trustees Of Tufts College Methodology for eliciting an analgesic response in a living subject
US5766605A (en) 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
JP3122319B2 (ja) 1994-05-02 2001-01-09 アソシエーティド ユニバーシティーズ，インコーポレイティド 錫−１１７ｍ−含有放射性治療剤
AU2431995A (en) 1994-05-09 1995-11-29 William J. Binder Method for reduction of headache pain
EP0760681B1 (en) 1994-05-31 1999-09-01 Allergan, Inc Modification of clostridial toxins for use as transport proteins
US5538733A (en) 1994-07-07 1996-07-23 Willmar Poultry Company, Inc. Method of priming an immune response in a one-day old animal
US5846216A (en) 1995-04-06 1998-12-08 G & P Technologies, Inc. Mucous membrane infusor and method of use for dispensing medications
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
AU6636096A (en) 1996-07-08 1998-02-02 University Of Massachusetts Dartmouth Novel proteins within the type e botulinum neurotoxin complex
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US7192596B2 (en) 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
GB9721189D0 (en) 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
US5955368A (en) * 1998-04-06 1999-09-21 Wisconsin Alumni Research Foundation Expression system for clostridium species
GB9818548D0 (en) * 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
US20040071736A1 (en) 1998-08-25 2004-04-15 Health Protection Agency Methods and compounds for the treatment of mucus hypersecretion
KR100876060B1 (ko) 1999-08-25 2008-12-26 알러간, 인코포레이티드 활성화가능한 재조합 신경독
US20090018081A1 (en) 1999-08-25 2009-01-15 Allergan, Inc. Activatable clostridial toxins
US20080032931A1 (en) 1999-08-25 2008-02-07 Steward Lance E Activatable clostridial toxins
US7740868B2 (en) 1999-08-25 2010-06-22 Allergan, Inc. Activatable clostridial toxins
US20030180289A1 (en) 1999-09-23 2003-09-25 Foster Keith Alan Inhibition of secretion from non-neuronal cells
US7138127B1 (en) 2000-01-19 2006-11-21 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US6641820B1 (en) * 2000-01-19 2003-11-04 Allergan, Inc. Clostridial toxin derivatives and methods to treat pain
US6500436B2 (en) * 2000-01-19 2002-12-31 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US7022329B2 (en) 2002-02-25 2006-04-04 Allergan, Inc. Method for treating neurogenic inflammation pain with botulinum toxin and substance P components
TW540386U (en) * 2002-07-02 2003-07-01 Lu-Rung Liau Device for massaging human body
GB0321344D0 (en) 2003-09-11 2003-10-15 Health Prot Agency Re-targeted toxin conjugates
DE102004043009A1 (de) 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
CA2588292C (en) 2004-12-01 2019-01-15 Health Protection Agency Non-cytotoxic protein conjugates
GB0426397D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
EP1830872B1 (en) 2004-12-01 2010-11-17 Health Protection Agency Fusion proteins
JP2008535486A (ja) 2005-03-15 2008-09-04 アラーガン、インコーポレイテッド クロストリジウム毒素標的細胞に対する改変された標的能力を有する修飾クロストリジウム毒素

Also Published As

Publication number Publication date
US7138127B1 (en) 2006-11-21
US20080317782A1 (en) 2008-12-25
US20070259003A1 (en) 2007-11-08
US7244437B2 (en) 2007-07-17
US20080095872A1 (en) 2008-04-24
US7622127B2 (en) 2009-11-24
US7833535B2 (en) 2010-11-16
US7736659B2 (en) 2010-06-15
US20060067929A1 (en) 2006-03-30
US7244436B2 (en) 2007-07-17
US20080317783A1 (en) 2008-12-25
US7262291B2 (en) 2007-08-28
US20060093625A1 (en) 2006-05-04
US7413742B2 (en) 2008-08-19
WO2001053336A1 (en) 2001-07-26
US20090010967A1 (en) 2009-01-08
US20060222666A1 (en) 2006-10-05
US20090042799A1 (en) 2009-02-12
US8017131B2 (en) 2011-09-13
AU2001227930A1 (en) 2001-07-31
US7056729B2 (en) 2006-06-06
US20080213311A1 (en) 2008-09-04
US20020068699A1 (en) 2002-06-06
US7780968B2 (en) 2010-08-24
US7425338B2 (en) 2008-09-16
US7704512B2 (en) 2010-04-27
US20070110769A1 (en) 2007-05-17

Similar Documents

Publication Publication Date Title
AR027234A1 (es) Derivados de la toxina clostridial y metodos para el tratamiento del dolor
Casley‐Smith et al. MODERN TREATMENT OF LYMPHOEDEMA II. THE BENZOPYRONES.
MXPA03002576A (es) Metodos para tratar lesiones musculares.
PT758900E (pt) Toxina botulinica para a reducao da dor de cabeca devida a enxaqueca
BR0110030A (pt) Método para tratamento de dor através da administração periférica de uma neurotoxina
CL2022002592A1 (es) Uso de agentes para el tratamiento de condiciones respiratorias
ATE296093T1 (de) Azalid-antibiotika zur topischen behandlung oder vorbeugung okulärer infektionen
WO2002007759A3 (en) Clostridial toxin derivatives and methods for treating pain
CY1120977T1 (el) Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι
BR0111800A (pt) Combinações de inibidores de depeptidil peptidase iv e outros agentes antidiabéticos para o tratamento de diabete mellitus
AR028939A1 (es) Metodo para tratar un desorden pancreatico con una neurotoxina
BR0111698A (pt) Método para o tratamento de um distúrbio de movimento
NO20021035L (no) Fremgangsmåter for anvendelse av rasktvirkende selective serotonin gjenopptakningsinhibitorer for behandling av seksuelldysfunksjon
EA200101089A1 (ru) Новый способ лечения
BR9510423A (pt) Formulação lipossomal multilamelar de baixa rigidez processo de tratamento ou de profilaxia de uma infecção bacteriana em um animal e de uma variante mucoìde da mesma, uso da formulação lipossomal antibacteriana
WO2001028491A3 (en) Method and composition for the treatment of dermatologic diseases
MY119375A (en) Treatment of tinnitus using neuroprotective agents
EP1383540A4 (en) METHODS AND PHARMACEUTICAL COMPOSITIONS FOR Wounds Healing
ES2125696T3 (es) Utilizacion del cloruro de tropsio para la produccion de una preparacion farmaceutica para el tratamiento de disfunciones vesicales.
BR9807796A (pt) Processos para tratar da incontinência urinária, de vertigem e da doença do movimento, e, composição farmacêutica.
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
BR9914794A (pt) Laxativo osmótico, não fermentado, para tratar e prevenir o câncer cólon-retal
BR0201974A (pt) Composição farmacêutica para tratamento de alterações do sono
SE0004101D0 (sv) New use
BR0115215A (pt) Método para o tratamento de inflamações

Legal Events

Date Code Title Description
FB Suspension of granting procedure